Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01264939
Registration number
NCT01264939
Ethics application status
Date submitted
20/12/2010
Date registered
22/12/2010
Date last updated
26/11/2013
Titles & IDs
Public title
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Query!
Scientific title
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
Query!
Secondary ID [1]
0
0
GA00889
Query!
Secondary ID [2]
0
0
Q4883g
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Chronic Idiopathic Urticaria
0
0
Query!
Condition category
Condition code
Skin
0
0
0
0
Query!
Dermatological conditions
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Allergies
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Autoimmune diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Omalizumab
Treatment: Drugs - Placebo
Treatment: Drugs - H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
Treatment: Drugs - Diphenhydramine
Placebo Comparator: Placebo - Participants received placebo subcutaneously every 4 weeks during the 24 week treatment period.
Experimental: Omalizumab 300 mg - Participants received omalizumab 300 mg subcutaneously every 4 weeks during the 24 week treatment period.
Treatment: Drugs: Omalizumab
Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
Treatment: Drugs: Placebo
Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
Treatment: Drugs: H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist
Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
Treatment: Drugs: Diphenhydramine
Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [1]
0
0
The percentage of participants with serious adverse events and other adverse events is summarized by MedDRA preferred terms and organ classes in the Reported Adverse Events section below.
Query!
Timepoint [1]
0
0
Baseline to the end of study (up to 40 weeks)
Query!
Secondary outcome [1]
0
0
Change From Baseline to Week 12 in the Weekly Itch Severity Score
Query!
Assessment method [1]
0
0
The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching. A negative change score indicates improvement.
Query!
Timepoint [1]
0
0
Baseline to Week 12
Query!
Secondary outcome [2]
0
0
Change From Baseline to Week 12 in the Urticaria Activity Score Over 7 Days (UAS7)
Query!
Assessment method [2]
0
0
The UAS7 is the sum of the daily urticarial activity scores over 7 days and ranges from 0 to 42. The daily urticarial activity score is the average of the morning and evening urticarial activity scores and ranges from 0 to 6. The urticarial activity score is the sum of ratings on a scale of 0 to 3 (0=none to 3=intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticarial activity scores over the 7 days prior to the first treatment. A higher urticarial activity score indicates more urticaria activity. A negative change score indicates improvement.
Query!
Timepoint [2]
0
0
Baseline to Week 12
Query!
Secondary outcome [3]
0
0
Change From Baseline to Week 12 in the Weekly Number of Hives Score
Query!
Assessment method [3]
0
0
The weekly hives score is the sum of the daily hives scores over 7 days and ranges from 0 to 21. The number of hives is measured twice daily (morning and evening) on a scale of 0 (none) to 3 (> 12 hives per 12 hours). The daily hives score is the average of the morning and evening scores. The Baseline score is the sum of the daily hives scores over the 7 days prior to the first treatment. A higher score indicates more hives. A negative change score indicates improvement.
Query!
Timepoint [3]
0
0
Baseline to Week 12
Query!
Secondary outcome [4]
0
0
Time to Minimally Important Difference (MID) Response in the Weekly Itch Severity Score by Week 12
Query!
Assessment method [4]
0
0
The time to the MID response is the number of weeks from the start of treatment (Baseline) until the time point at which the first MID response occurs. The MID response is defined as a reduction = 5 points from Baseline in the weekly itch severity score. The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching.
Query!
Timepoint [4]
0
0
Baseline to Week 12
Query!
Secondary outcome [5]
0
0
Percentage of Participants With a UAS7 Score = 6 at Week 12
Query!
Assessment method [5]
0
0
The UAS7 is the sum of the daily urticarial activity scores over 7 days and ranges from 0 to 42. The daily urticarial activity score is the average of the morning and evening urticarial activity scores and ranges from 0 to 6. The urticarial activity score is the sum of ratings on a scale of 0 to 3 (0=none to 3=intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticarial activity scores over the 7 days prior to the first treatment. A higher urticarial activity score indicates more urticaria activity.
Query!
Timepoint [5]
0
0
Week 12
Query!
Secondary outcome [6]
0
0
Percentage of Weekly Itch Severity Score MID Responders at Week 12
Query!
Assessment method [6]
0
0
The percentage of participants with an itch severity score at 12 Weeks at least 5 points lower than at Baseline. The weekly itch severity score is the sum of the daily itch severity scores over 7 days and ranges from 0 to 21. The daily itch severity score is the average of the morning and evening scores on a scale of 0 (none) to 3 (severe). The Baseline weekly itch severity score is the sum of the daily itch severity scores over the 7 days prior to the first treatment. A higher itch severity score indicates more severe itching.
Query!
Timepoint [6]
0
0
Baseline to Week 12
Query!
Secondary outcome [7]
0
0
Change From Baseline to Week 12 in the Weekly Size of the Largest Hive Score
Query!
Assessment method [7]
0
0
The weekly size of the largest hive score is the sum of the daily size of the largest hive scores over 7 days and ranges from 0 to 21. The daily size of the largest hive score is assessed twice daily (morning and evening) on a scale of 0 (none) to 3 (> 2.5 cm). The daily size of the largest hive score is the average of the morning and evening scores. The Baseline weekly size of the largest hive score is calculated over the 7 days prior to the first treatment. A higher score indicates larger hives. A negative change score indicates a reduction in hive size.
Query!
Timepoint [7]
0
0
Baseline to Week 12
Query!
Secondary outcome [8]
0
0
Change From Baseline in the Overall Dermatology Life Quality Index (DLQI) Score at Week 12
Query!
Assessment method [8]
0
0
The DLQI is a 10-item dermatology-specific health-related quality of life measure. Patients rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives on a scale of 0 (Not at all) to 3 (Very much). The overall DLQI is the sum of the responses to the 10 items and ranges from 0 to 30. A lower score indicates a better quality of life. A negative change score indicates improvement.
Query!
Timepoint [8]
0
0
Baseline to Week 12
Query!
Secondary outcome [9]
0
0
Percentage of Angioedema-free Days From Week 4 to Week 12
Query!
Assessment method [9]
0
0
The percentage of angioedema-free days from Weeks 4 to 12 was defined as the number of days for which a patient responded "No" to the angioedema question in the daily diary divided by the total number of days with a non-missing diary entry, starting at the Week 4 visit and ending the day prior to the Week 12 visit.
Query!
Timepoint [9]
0
0
Week 4 to Week 12
Query!
Secondary outcome [10]
0
0
Percentage of Complete Responders (UAS7 = 0) at Week 12
Query!
Assessment method [10]
0
0
A complete responder was defined as a participant with a UAS7 score = 0 at Week 12. The UAS7 is the sum of the daily urticarial activity scores over 7 days and ranges from 0 to 42. The daily urticarial activity score is the average of the morning and evening urticarial activity scores and ranges from 0 to 6. The urticarial activity score is the sum of ratings on a scale of 0 to 3 (0=none to 3=intense/severe) for (1) the number of wheals (hives) and (2) itch intensity over the previous 12 hours, ranges from 0 to 6, and is measured twice daily (morning and evening). The Baseline score is the sum of the daily urticarial activity scores over the 7 days prior to the first treatment. A higher urticarial activity score indicates more urticaria activity.
Query!
Timepoint [10]
0
0
Week 12
Query!
Eligibility
Key inclusion criteria
- Diagnosis of chronic idiopathic urticaria (CIU) refractory to H1 antihistamines, H2
blockers, and/or leukotriene receptor antagonists (LTRA) at the time of randomization.
- The presence of itch and hives for > 6 consecutive weeks at any time prior to
enrollment despite current use of H1 antihistamine (up to 4 times the approved
dosage), H2 blocker, and/or LTRA treatment during this time.
- Urticaria activity score over 7 days (UAS7) score (range 0-42) = 16 and itch
component of UAS7 (range 0-21) = 8 during 7 days prior to randomization (Week 0).
- In-clinic UAS = 4 on at least one of the screening visit days (Day -14, Day -7,
or Day 1).
- For women of childbearing potential, agreement to use an acceptable form of
contraception and to continue its use for the duration of the study.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Treatment with an investigational agent within 30 days prior to screening.
- Weight less than 20 kg (44 lbs).
- Clearly defined underlying etiology for chronic urticarias other than CIU.
- Evidence of parasitic infection.
- Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or
other skin disease associated with itch.
- Previous treatment with omalizumab within a year prior to screening.
- Routine doses of the following medications within 30 days prior to screening: Systemic
or cutaneous (topical) corticosteroids (prescription or over the counter),
hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide.
- Intravenous (IV) immunoglobulin G (IVIG), or plasmapheresis within 30 days prior to
screening.
- Regular (daily/every other day) doxepin (oral) use within 6 weeks prior to screening.
- Patients with current malignancy, history of malignancy, or currently under work-up
for suspected malignancy except non-melanoma skin cancer that has been treated or
excised and is considered resolved.
- Hypersensitivity to omalizumab or any component of the formulation.
- History of anaphylactic shock.
- Presence of clinically significant cardiovascular, neurological, psychiatric,
metabolic, or other pathological conditions that could interfere with the
interpretation of the study results and or compromise the safety of the patients.
- Evidence of current drug or alcohol abuse.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/11/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
336
Query!
Recruitment in Australia
Recruitment state(s)
ACT,QLD,VIC
Query!
Recruitment hospital [1]
0
0
- Canberra
Query!
Recruitment hospital [2]
0
0
- Brisbane
Query!
Recruitment hospital [3]
0
0
- Carlton
Query!
Recruitment hospital [4]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2605 - Canberra
Query!
Recruitment postcode(s) [2]
0
0
4102 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Indiana
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Iowa
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Kentucky
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Minnesota
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Montana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New Jersey
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Ohio
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oregon
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Vermont
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Berlin
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Erlangen
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Freiburg
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Hamburg
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Koeln
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Lübeck
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Mainz
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Marburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Tübingen
Query!
Country [34]
0
0
New Zealand
Query!
State/province [34]
0
0
Auckland
Query!
Country [35]
0
0
New Zealand
Query!
State/province [35]
0
0
Beckenham
Query!
Country [36]
0
0
New Zealand
Query!
State/province [36]
0
0
Tauranga
Query!
Country [37]
0
0
New Zealand
Query!
State/province [37]
0
0
Wellington
Query!
Country [38]
0
0
Poland
Query!
State/province [38]
0
0
Krakow
Query!
Country [39]
0
0
Poland
Query!
State/province [39]
0
0
Lodz
Query!
Country [40]
0
0
Poland
Query!
State/province [40]
0
0
Warszawa
Query!
Country [41]
0
0
Singapore
Query!
State/province [41]
0
0
Singapore
Query!
Country [42]
0
0
Switzerland
Query!
State/province [42]
0
0
Aarau
Query!
Country [43]
0
0
Switzerland
Query!
State/province [43]
0
0
Bern
Query!
Country [44]
0
0
Switzerland
Query!
State/province [44]
0
0
St. Gallen
Query!
Country [45]
0
0
United Kingdom
Query!
State/province [45]
0
0
Cambridge
Query!
Country [46]
0
0
United Kingdom
Query!
State/province [46]
0
0
Leicester
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
London
Query!
Country [48]
0
0
United Kingdom
Query!
State/province [48]
0
0
Norwich
Query!
Country [49]
0
0
United Kingdom
Query!
State/province [49]
0
0
Oxford
Query!
Country [50]
0
0
United Kingdom
Query!
State/province [50]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is a global Phase III, multicenter, randomized, double-blind, placebo controlled,
parallel-group study to evaluate the safety and efficacy of omalizumab administered
subcutaneously as an add-on therapy for the treatment of adolescent and adult patients aged
12-75 who have been diagnosed with chronic idiopathic urticaria (CIU) who remain symptomatic
despite standard-dosed H1 antihistamine treatment (including doses up to 4 times above the
approved dose level), H2 blockers, and/or leukotriene receptor antagonists (LTRA).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01264939
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Edward R. Conner, M.D.
Query!
Address
0
0
Genentech, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01264939
Download to PDF